MA-PRESS-GANEY/FORSTA
27.4.2022 15:02:07 CEST | Business Wire | Press release
Press Ganey , renowned leader in patient, member, employee and consumer experience across the healthcare ecosystem, announced it has completed its acquisition of Forsta , a leading global provider of market research, customer experience (CX) and employee experience (EX) technology. The closing is effective as of April 26, 2022.
As industry-recognized leaders, with Press Ganey recently selected Best in KLAS for Patient Experience Improvement and Forsta named a Leader in the 2021 Gartner® Magic Quadrant™ for Voice of the Customer , the combined companies will power the future of research and experience technology.
“Together, Press Ganey and Forsta offer our clients the data connectivity, accelerated analytics, DEI expertise and deeply segmented insights that companies need to deliver frictionless experiences and truly drive transformation,” said Patrick T. Ryan, chairman and chief executive officer, Press Ganey. “With Forsta, we expand into new geographies and industries, with highly complementary market research, CX and EX technology that will coordinate seamlessly with our existing healthcare solutions.”
“Press Ganey is expediting Forsta’s mission to reinvent the global insights industry. With this investment, we will be able to greatly accelerate innovation so our customers can deliver better insights, faster and at scale,” said Kyle Ferguson, chief executive officer, Forsta. “There is tremendous opportunity from the convergence of our resources, and we have no plans to slow down.”
Acquisition Highlights
Fast-tracked Product Innovation. Press Ganey’s investment will advance Forsta’s product innovation at an accelerated pace, especially in the high-demand areas of artificial intelligence (AI), data visualization and qualitative research.
Marketplace Expansion. Forsta’s global presence and extensive network will propel Press Ganey’s international healthcare growth ambitions while also expanding the company into new verticals, such as retail, financial services and consumer goods.
Unparalleled Insights. Both companies are proven changemakers and bring proprietary research and thought leadership to deliver key insights that tackle essential issues, like barriers to human-centered data , employee burnout and advancing health equity .
Healthcare Sector Disruption. Backed by blue-chip consulting, unparalleled experience measurement expertise and proprietary analytics to help drive improvement, Press Ganey will offer breakthrough advancements to the evolving healthcare marketplace. A new suite of purpose-built for healthcare, self-service solutions are immediately available, like digital communities, virtual focus groups, crowdsourcing and more.
Exceptional Human Capital. Two empowered, elite workforces will come together around aligned missions and pursuits to seamlessly turn data into meaningful insights that drive impact.
The joint company will continue to be led by Ryan as chairman and CEO, and Ferguson will remain at the helm of Forsta as CEO. Combined, the organization’s 3,000+ employees now serve thousands of customers, including Fortune 500 companies and top healthcare systems, throughout the North America, EMEA (Europe-Middle East-Africa) and APAC (Asia-Pacific) regions.
About Press Ganey
Press Ganey invented the healthcare performance improvement movement over 35 years ago. Today it offers an integrated suite of solutions that address safety, clinical excellence, patient experience and workforce engagement. The company works with more than 41,000 healthcare facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality and experience of care.
About Forsta
Forsta powers an Experience and Research Technology Platform that gathers and analyzes data, and translates the findings into shareable actions to inform decision-making and drive growth. Forsta’s technology, combined with its team of expert consultants, help organizations better understand the full Human Experiences (HX) of their audiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005008/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom